204 related articles for article (PubMed ID: 28355968)
1. Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature.
Dineen M; Hansen E; Guancial E; Sievert L; Sahasrabudhe D
J Oncol Pharm Pract; 2018 Jun; 24(4):314-318. PubMed ID: 28355968
[TBL] [Abstract][Full Text] [Related]
2. Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: A case report and review of the literature.
Ould-Nana I; Cillis M; Gizzi M; Gillion V; Hantson P; Gérard L
J Oncol Pharm Pract; 2021 Jan; 27(1):216-219. PubMed ID: 32397905
[TBL] [Abstract][Full Text] [Related]
3. Abiraterone-induced rhabdomyolysis: A case report.
Moore DC; Moore A
J Oncol Pharm Pract; 2017 Mar; 23(2):148-151. PubMed ID: 26637407
[TBL] [Abstract][Full Text] [Related]
4. Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report.
Neyra JA; Rocha NA; Bhargava R; Vaidya OU; Hendricks AR; Rodan AR
BMC Nephrol; 2015 Jul; 16():118. PubMed ID: 26220655
[TBL] [Abstract][Full Text] [Related]
5. Statin-Induced Rhabdomyolysis Due to Pharmacokinetic Changes From Biliary Obstruction in a Patient With Metastatic Prostate Cancer.
Desikan SP; Sobash P; Fisher A; Desikan R
J Investig Med High Impact Case Rep; 2020; 8():2324709620947275. PubMed ID: 32755252
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis.
Karakurt Eryılmaz M; Karaağaç M
J Oncol Pharm Pract; 2019 Dec; 25(8):2031-2034. PubMed ID: 31694496
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
8. Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience.
Ramudo-Cela L; Balea-Filgueiras J; Vizoso-Hermida JR; Martín-Herranz I
J Oncol Pharm Pract; 2017 Dec; 23(8):615-619. PubMed ID: 27753628
[TBL] [Abstract][Full Text] [Related]
9. Cancer therapeutics-related cardiac dysfunction in a patient treated with abiraterone for castration-resistant prostate cancer.
Tsugu T; Nagatomo Y; Nakajima Y; Kageyama T; Akise Y; Endo J; Itabashi Y; Murata M; Mitamura H
J Med Ultrason (2001); 2019 Apr; 46(2):239-243. PubMed ID: 30151629
[TBL] [Abstract][Full Text] [Related]
10. Ticagrelor-induced acute kidney injury can increase serum concentration of statin and lead to concurrence of rhabdomyolysis.
Park IS; Lee SB; Song SH; Seong EY; Kim IY; Rhee H; Kim MJ; Lee DW
Anatol J Cardiol; 2018 Mar; 19(3):225-226. PubMed ID: 29521318
[No Abstract] [Full Text] [Related]
11. A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.
Lin J; Patel SA; Sama AR; Hoffman-Censits JH; Kennedy B; Kilpatrick D; Ye Z; Yang H; Mu Z; Leiby B; Lewis N; Cristofanilli M; Kelly WK
Oncologist; 2016 Nov; 21(11):1296-1297e. PubMed ID: 28178640
[TBL] [Abstract][Full Text] [Related]
12. Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.
Conteduca V; Caffo O; Derosa L; Veccia A; Petracci E; Chiuri VE; Santoni M; Santini D; Fratino L; Maines F; Testoni S; De Giorgi U
Prostate; 2015 Sep; 75(12):1329-38. PubMed ID: 25982919
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
[TBL] [Abstract][Full Text] [Related]
14. [Use of abiraterone acetate in the treatment of patients with metastatic castration resistant prostate cancer and no prior chemotherapy: 3 case reports and literature review].
Ma H; Zhu G; Wan B; Wu PJ; Wang JY
Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Aug; 46(4):653-6. PubMed ID: 25131489
[TBL] [Abstract][Full Text] [Related]
15. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
Montgomery B; Kheoh T; Molina A; Li J; Bellmunt J; Tran N; Loriot Y; Efstathiou E; Ryan CJ; Scher HI; de Bono JS
Eur Urol; 2015 May; 67(5):866-73. PubMed ID: 25018037
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE;
Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341
[TBL] [Abstract][Full Text] [Related]
17. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
[TBL] [Abstract][Full Text] [Related]
18. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
McKay RR; Werner L; Mostaghel EA; Lis R; Voznesensky O; Zhang Z; Marck BT; Matsumoto AM; Domachevsky L; Zukotynski KA; Bhasin M; Bubley GJ; Montgomery B; Kantoff PW; Balk SP; Taplin ME
Clin Cancer Res; 2017 Feb; 23(4):935-945. PubMed ID: 27683182
[No Abstract] [Full Text] [Related]
20. Subarachnoid hemorrhage and rhabdomyolysis induced acute renal failure complicating organophosphate intoxication.
Gokel Y
Ren Fail; 2002 Nov; 24(6):867-71. PubMed ID: 12472209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]